Login to Your Account



Strict Criteria, Statistical Success

Parkinson's Gene Therapy Successful in Blinded Trial

By Anette Breindl


Thursday, March 17, 2011
In a double-blind, randomized controlled trial of Neurologix Inc.'s gene therapy NLX-P101, Parkinson's disease patients showed a statistically significant improvement in their scores on a scale used to measure motor symptoms six months after their surgery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription